Seres Therapeutics receives $50 million from Nestlé Health Science
CAMBRIDGE, Mass. - Seres Therapeutics, Inc. (NASDAQ:MCRB), a clinical-stage biotherapeutic company with a market ...
Seres Receives $50 Mln Installment Payment Towards Sale Of VOWST Business To Nestle Health Science
Seres Therapeutics, Inc. (MCRB), a live biotherapeutics company, Thursday said that it has received a $50 million installment payment ...
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company’s ...
Nature4y
Nestlé: A journey of research and innovation in the fight against allergies
Nestlé pledges in favour of science-based allergen labelling that is clear and trustworthy for consumers, and harmonised so that allergic consumers find the level of information that is relevant ...
pharmaphorum1y
Nestle sells underperforming peanut allergy drug
"At the same time, the divestiture allows Nestle Health Science to focus on its core strengths and key growth drivers," he added. Nestle acquired Aimmune with high hopes that Palforzia would ...
Reuters19d
Judge will not dismiss lawsuit claiming Poland Spring water is not from a spring
Ds Services Of America, Inc. Dec 31 (Reuters) - A federal judge in Connecticut refused to dismiss a long-running lawsuit accusing the former Nestle Waters North America of defrauding consumers by ...